ELMO2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: ELMO2

NCBI ID: G63916

ELMO2

ELMO2: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

ELMO2 (Ced-12 homolog 2) is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns have made it an attractive target for researchers to study, and recent studies have shed light on its role in these conditions.

ELMO2 is a gene that encodes a protein known as ELMO2, which is a key regulator of the microtubules that exist in the cells. Microtubules are important structural elements that help keep cells in shape and move efficiently, and they are also involved in many cellular processes, including cell division, intracellular transport, and cell signaling. The disruption of microtubules has been linked to a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of ELMO2 is its ability to interact with several different proteins, including microtubule-associated proteins (MAPs) and microtubule-remodeling proteins (MRP). MAPs are involved in regulating microtubule dynamics and are thought to play a key role in the development of many diseases, including cancer. MRP proteins, on the other hand, are involved in the regulation of microtubule stability and dynamics, and are also thought to be involved in the development of many diseases.

ELMO2 has been shown to be involved in the regulation of microtubule dynamics in various cell types, including cancer cells. For example, studies have shown that ELMO2 is highly expressed in many cancer cells and that it is involved in the regulation of microtubule stability in these cells. Additionally, experiments have shown that inhibiting the activity of ELMO2 can lead to the breakdown of microtubules in cancer cells, which can have a negative impact on their growth and survival.

Another potential role of ELMO2 is its involvement in neurodegenerative diseases. Neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of neural cells and their associated structures, leading to a range of symptoms and disabilities. ELMO2 has been shown to be involved in the regulation of microtubule dynamics in neurons, and disruptions in microtubule stability have been linked to the development of neurodegenerative diseases. For example, studies have shown that ELMO2 is involved in the regulation of microtubule dynamics in the brain and that its activity is disrupted in neurodegenerative disease models.

ELMO2 has also been shown to be involved in autoimmune disorders. Autoimmune disorders are a group of conditions in which the immune system attacks the body's own tissues, leading to a range of symptoms and disabilities. ELMO2 has been shown to be involved in the regulation of microtubule dynamics in immune cells, and disruptions in microtubule stability have been linked to the development of autoimmune disorders. For example, studies have shown that ELMO2 is involved in the regulation of microtubule dynamics in T cells, which are a key part of the immune system, and that its activity is disrupted in autoimmune disease models.

In conclusion, ELMO2 is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and expression patterns have made it an attractive target for researchers to study, and recent studies have shed light on its role in these conditions. Further research is needed to fully understand the role of ELMO2 in these diseases and to develop effective treatments.

Protein Name: Engulfment And Cell Motility 2

Functions: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Acts in association with DOCK1 and CRK. Was initially proposed to be required in complex with DOCK1 to activate Rac Rho small GTPases. May enhance the guanine nucleotide exchange factor (GEF) activity of DOCK1

The "ELMO2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELMO2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets